Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 5/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31397009 | 0.93 | TLR9 (0.35) | NAMPTPRMT5WDR77GRM5GRM1 | |
| SCHEMBL30026606 | 0.92 | NAMPT (0.40) | NAMPTPRMT5WDR77GRM5GRM1 | |
| SCHEMBL23540834 | 0.92 | NAMPT (0.40) | NAMPTPRMT5WDR77GRM5GRM1 | |
| SCHEMBL30273787 | 0.91 | NAMPT (0.38) | NAMPTPRMT5WDR77GRM5GRM1 | |
| SCHEMBL30273631 | 0.89 | TLR9 (0.36) | PRMT5GRM5GPR119 | |
| SCHEMBL31323560 | 0.88 | PRMT5 (0.37) | PRMT5GPR119CYP11B2 | |
| SCHEMBL30258845 | 0.88 | TNF (0.43) | GRM5GRM1PDK4BTKHTR6 | |
| SCHEMBL30273878 | 0.88 | PRMT5 (0.38) | NAMPTPRMT5WDR77GRM5GRM1 | |
| SCHEMBL24821127 | 0.88 | GRM5 (0.35) | PRMT5GRM5LNPEP | |
| SCHEMBL23541226 | 0.86 | GHSR (0.35) | PRMT5GRM5BRD4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12599672-B2 | KRAS proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC | 2025-10-02 | — | — | US | disclosed |
| US-20250144225-A1 | KRAS Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025076044-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | PAQ Therapeutics Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250018046-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. | 2025-01-16 | — | — | US | disclosed |
| WO-2025006753-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | MERCK PATENT GMBH (DE) | 2025-01-02 | — | — | WO | disclosed |
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | ABBVIE INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| EP-4384512-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | Calico Life Sciences LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-117957225-A | Compounds for targeting degradation of IRAK4 proteins | 渤健马萨诸塞州股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117940414-A | Compounds for targeting IRAK4 protein degradation | 渤健马萨诸塞州股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023059792-A1 | CORONAVIRUS NON-STRUCTURAL PROTEIN 3 DEGRADING COMPOUNDS | C4 THRAPEUTICS, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023055952-A1 | NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) DEGRADING COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023019166-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023283610-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023283372-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-4077319-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021127586-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127586-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599672-B2 | KRAS proteolysis targeting chimeras | KRAS, HRAS, NRAS | NAMPT 4874/4885PRMT5 1834/4885WDR77 733/4885 |
| US-20250018046-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | NAMPT 3474/4885PRMT5 845/4885WDR77 252/4885 |
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | PTPN5, PTPN1, PTPN2 | NAMPT 1623/4885PRMT5 303/4885WDR77 2088/4885 |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | PTPN1, PTPN2, PTPN18 | NAMPT 793/4885PRMT5 1555/4885WDR77 2601/4885 |
| US-20250144225-A1 | KRAS Proteolysis Targeting Chimeras | KRAS, HRAS, NRAS | NAMPT 3835/4885PRMT5 820/4885WDR77 401/4885 |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | NAMPT 3630/4885PRMT5 1110/4885WDR77 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.